Associate Director, Clinical Biomarker Development

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC‑6236), elironrasib (RMC‑6291), zoldonrasib (RMC‑9805), and RMC‑5127 are currently in clinical development.

The Associate Director in the Clinical Biomarker Development team, within Translational Medicine, will play a key role in the design, execution, and interpretation of clinical biomarker strategies across Revolution Medicines’ oncology pipeline.

• Develop and maintain translational and clinical biomarker strategies to support portfolio assets from phase 1 to phase 3 studies.
• Support the development of biomarker related aspects of the trial design, including assay development, patient sample acquisition, study protocols, clinical biomarker plans, and other regulatory documents.
• Participate in cross‑functional teams such as clinical working groups and clinical study execution teams.
• Work with internal translational groups, contract research organizations, and collaborators to develop and validate assays for clinical use.
• Manage outsourcing to CROs, oversee the development of scope of work, contracting, budgets, and timelines.
• Collaborate with Clinical Bioinformatics and Cancer Genomics to support analysis of biomarker readouts and present outputs to internal and external stakeholders.

• Ph.D. in cancer biology, cell/molecular biology, genomics or equivalent.
• 3+ years of clinical biomarker and/or assay development experience in industry.
• Experience and track‑record of the development, validation, and clinical implementation of biomarker readouts.
• Experience of working with Contract Research Organizations to deliver biomarker readouts.
• Excellent scientific and business communication skills, strong interpersonal/collaboration skills and planning skills.
• Ability to think critically and creatively and to work independently to determine appropriate resources for resolution of problems.
• Ability to multi‑task and thrive in a fast‑paced innovative environment.

• Experience with targeted oncology therapies or RAS/MAPK pathway biology.
• Biological understanding of pancreatic, non‑small cell lung and/or colorectal cancers.
• Familiarity with biomarker platforms such as genomic, transcriptomic and proteomic assays.
• Familiarity with analytical software and capabilities for integrating clinical and biomarker datasets.

Hybrid – offices in Redwood City, CA with flexibility for remote work.

$186,000 – $233,000 USD

Revolution Medicines is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital status, medical condition, and veteran status.